Company profile
Acro Biomedical Co., Ltd.
OTC: ACBM · Healthcare · Medical - Pharmaceuticals
#1161 of 1,418 Healthcare companies by revenue
EA Score
16DFH 4DQ 32GM 21SS 19
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ workforce scale, 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$101.1k
Employees
1
as of 2026-08-25
Market cap
$1.6M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$101.1k-$101.1k2025
Operating income-$154.0k-$154.0k2025
Total assets$14.1k$14.1k2025
Liabilities$326.9k$326.9k2024
Equity-$387.0k-$387.0k2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Acro Biomedical Co., Ltd.’s revenue?
Acro Biomedical Co., Ltd. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Protagenic Therapeutics, Inc.——Welsis Corp.20DAzitra, Inc.29DCity View Green Holdings Inc.——Anything Technologies Media, Inc.32DOncology Pharma Inc.——Neighbors
Hamilton →Key facts
CEOYu-Ting Su
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersFishers, IN
ExchangeOTC: ACBM
Employees1
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.